What’s in a Drug Name?

What’s in a Drug Name? Did you ever wonder at the bizarre brand names born by your favorite medicines? If so, you’ve probably guessed brand-name rule No. 1: They don’t actually mean anything.


Rise in biotech lawsuits

Rise in biotech lawsuits Biotech companies were served with 17 percent of all U.S. shareholder suits last year, according to PricewaterhouseCoopers’ Securities Litigation Study of 2003. By contrast, biotech’s estimated 350 public companies make up only 2 percent of the approximately 17,000 firms publicly traded in the United States.


Agriculture Department looks at revamping biotech rules

Agriculture Department looks at revamping biotech rules Worried about the inadvertent spread of new bioengineered plants that produce drugs and chemicals, the Agriculture Department is studying whether to adopt a risk-based system to protect the environment and food supply.


Making Way for Designer Insects

Making Way for Designer Insects The insect world could shortly undergo a genetic makeover in the laboratory. Scientists are at work developing silkworms that produce pharmaceuticals instead of silk, honeybees resilient enough to resist pesticides and even mosquitoes capable of delivering vaccines, instead of disease, with every bite.


Biotech firms urge Canada to uphold canola patent

Biotech firms urge Canada to uphold canola patent Representatives for scientists and biotech firms warned Tuesday that companies could abandon Canada unless the Supreme Court upholds a patent for canola that has been modified to resist a certain type of weedkiller.


Biotech Limits Found Lacking

Biotech Limits Found Lacking Techniques for limiting the spread of genetically engineered salmon, corn and other organisms are still in their infancy, and far more work needs to be done to make sure the new products don’t taint the food supply or wipe out important species, a National Research Council panel said yesterday.


FDA's economist in chief

FDA’s economist in chief Foes and friends of Mark McClellan agree on at least one point: The Food and Drug Administration commissioner is very popular with the drug industry he regulates. This article profiles opinions of Mark McClennan’s performance as FDA commissioner.


FDA’s economist in chief

FDA’s economist in chief Foes and friends of Mark McClellan agree on at least one point: The Food and Drug Administration commissioner is very popular with the drug industry he regulates. This article profiles opinions of Mark McClennan’s performance as FDA commissioner.


Biotech IPOs; don't let the numbers deceive

Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital — its second-best year ever. Yet, many of the biotech companies that went public in the last quarter of the year were miserable after-market performers.


Biotech IPOs; don’t let the numbers deceive

Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital — its second-best year ever. Yet, many of the biotech companies that went public in the last quarter of the year were miserable after-market performers.


Do NOT follow this link or you will be banned from the site!